

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

May 8, 2013

(Date of earliest event reported)

**LABORATORY CORPORATION OF
AMERICA HOLDINGS**

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or other jurisdiction of Incorporation)

1-11353

(Commission File Number)

13-3757370

(I.R.S. Employer Identification No.)

**358 South Main Street,
Burlington, North Carolina**

(Address of principal executive offices)

27215

(Zip Code)

336-229-1127

(Registrant's telephone number including area
code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

Summary information of the Company in connection with its Annual Meeting of Stockholders in Burlington, North Carolina on May 8, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant

By: /s/ F. SAMUEL EBERTS III
F. Samuel Eberts III
Chief Legal Officer and Secretary

May 8, 2013




2013 ANNUAL MEETING OF STOCKHOLDERS


MAY 8, 2013 | BURLINGTON, NC

FORWARD LOOKING STATEMENT

This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2012, and subsequent SEC filings.





MISSION STATEMENT

**We Will Be a Trusted Knowledge Partner
for Stakeholders, Leading to Growth in Our Business and
Continued Creation of Shareholder Value**


We Will Achieve This Mission by Continuing to Execute
Our Five Pillar Strategy



**Deploy Capital to Investments
That Enhance Our Business and
Return Capital to Shareholders**



10.3% FCF CAGR from 2001-2012



Note: 2011 Free Cash Flow calculation above does not include the \$49.5 million Hunter Labs settlement
 Free Cash Flow is a non-GAAP metric (see reconciliation of non-GAAP Financial Measures included herein)
 Free Cash Flow CAGR calculation uses 2001 data (2001 Free Cash Flow was \$228 million)

Five-Year Capital Snapshot

- Acquisitions: Genzyme Genetics*, Orchid Cellmark, MEDTOX Scientific
- Approximately \$2.1 billion of share repurchase since 2008
- Approximate 50/50 split between acquisitions and share repurchase since 2008

LabCorp Capital Deployment

	2008	2009	2010	2011	2012	Total
Cash from Operating Activities	\$ 780.9	\$ 862.4	\$ 883.6	\$ 855.6	\$ 841.4	\$4,223.9
Total Capital Deployed	\$ 839.2	\$ 603.6	\$1,650.0	\$ 927.9	\$1,025.4	\$5,046.1
Capital Expenditures	\$ 156.7	\$ 114.7	\$ 126.1	\$ 145.7	\$ 173.8	\$ 717.0
% Total Capital Deployed	19%	19%	8%	16%	17%	14%
Cash Used for Acquisitions	\$ 348.9	\$ 215.9	\$1,185.8	\$ 138.3	\$ 335.1	\$2,224.0
% Total Capital Deployed	42%	36%	72%	15%	33%	44%
Cash Used for Share Repurchase	\$ 333.6	\$ 273.0	\$ 338.1	\$ 643.9	\$ 516.5	\$2,105.1
% Total Capital Deployed	40%	45%	20%	69%	50%	42%

Source: SEC Filings

*GENZYME GENETICSSM and its logo are trademarks of Genzyme Corporation and used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of LabCorp, under license. Esoterix Genetic Laboratories and LabCorp are operated independently from Genzyme Corporation.

**Enhance IT Capabilities
To Improve Physician
and Patient Experience**



LabCorp Beacon™ Platform

- **Rich web portal and mobility framework**
 - Physician, Patient and Payor portals
 - Mobility solutions
- **Enhanced Efficiency and Service**
 - Online appointment scheduling
 - Express Orders
 - AccuDraw™
 - Integrated results, enhanced reports
- **Lab Analytics**
 - One-click trending of patient, test and population
 - View lab history
- **Services Oriented Architecture**
 - Rules based engines
 - Content aggregation
 - Plug in model for seamless integration with practice workflow
 - Scalable, big data model

Continue to Improve Efficiency to Offer the Most Compelling Value in Laboratory Services



Our Focus on Efficiency

- Constant focus on cost structure
- Standardization
 - Lab platforms, instruments and processes
 - Billing system
- Supply chain optimization
- Automation of pre-analytics
- Facility rationalization
- Propel splitting and sorting robotics



PR > PEL

**Scientific Innovation
At Appropriate Pricing**



Companion diagnostics and personalized medicine

- IL-28B
- BRAF V600E metastatic melanoma (Zelboraf)
- Vysis ALK Break Apart FISH probe (XALKORI)
- K-RAS
- HLA-B* 5701
- EGFR Mutation Analysis
- HCV GenoSure® NS3/4A
- PhenoSense®, PhenoSense GT®
- HERmark®
- SNP Microarray-Oncology
- CYP 450 2C19

Our core competencies in science, IT and personalized medicine make LabCorp an attractive partner for drug development

Women's health


- ROMA
- Nuswab STD testing on a single swab
- Expanded Vaginosis and Candida testing
- Expanded options for HPV DNA testing
- Age-based guideline testing initiative for HPV
- Non-Invasive Prenatal Screening

Development of Knowledge Services




Fundamental Changes in Healthcare “Center of Gravity”

- Health systems
- IDNs
- ACOs
- PCMHs
- Mega-physician practices
- Managed care collaborations with and ownership of all of the above



EXCELLENT PERFORMANCE

Revenue and Adjusted EPS Excluding Amortization Growth: 2007 – 2012 ^{1,2,3}



1. Excluding the \$0.25 per diluted share impact of restructuring and other special charges and the \$0.27 per diluted share impact from amortization in 2007; excluding the \$0.44 per diluted share impact of restructuring and other special charges and the \$0.31 per diluted share impact from amortization in 2008; excluding the (\$0.09) per diluted share impact of restructuring and other special charges and the \$0.35 per diluted share impact from amortization in 2009; excluding the \$0.26 per diluted share impact of restructuring and other special charges and the \$0.43 per diluted share impact from amortization in 2010; excluding the \$0.72 per diluted share impact of restructuring and other special charges, the \$0.03 per diluted share impact from a loss on the divestiture of assets and the \$0.51 per diluted share impact from amortization in 2011; excluding the \$0.29 per diluted share impact of restructuring and other special charges and the \$0.54 per diluted share impact from amortization in 2012

2. EPS, as presented represents adjusted, non-GAAP financial measures. Diluted EPS, as reported in the Company's Annual Report were: \$3.93 in 2007; \$4.16 in 2008; \$4.98 in 2009; \$5.29 in 2010; \$5.11 in 2011; and \$5.99 in 2012

3. 2008 revenue includes a \$7.5 million adjustment relating to certain historic overpayments made by Medicare for claims submitted by a subsidiary of the Company

RECONCILIATION FREE CASH FLOW

Reconciliation of non-GAAP Financial Measures

(In millions, except per share data)

	<u>2012</u>	<u>2011</u>	<u>2010</u>	<u>2009</u>	<u>2008</u>	<u>2007</u>	<u>2006</u>	<u>2005</u>	<u>2004</u>	<u>2003</u>	<u>2002</u>
Cash flows from operations ¹	\$841.4	\$905.1	\$883.6	\$862.4	\$780.9	\$709.7	\$632.3	\$574.2	\$538.1	\$564.3	\$444.9
Capital expenditures	(173.8)	(145.7)	(126.1)	(114.7)	(156.7)	(142.6)	(115.9)	(93.6)	(95.0)	(83.6)	(74.3)
Free cash flow ²	<u>667.6</u>	<u>759.4</u>	<u>757.5</u>	<u>747.7</u>	<u>624.2</u>	<u>567.1</u>	<u>516.4</u>	<u>480.6</u>	<u>443.1</u>	<u>480.7</u>	<u>370.6</u>
Weighted average diluted shares outstanding	97.4	101.8	105.4	109.1	111.8	121.3	134.7	144.9	150.7	144.8	144.2

(1) 2011 cash flows from operations excludes the \$49.5 million Hunter Labs settlement payment

(2) Free cash flow represents cash flows from operations less capital expenditures



www.LabCorp.com

